July 11, 2014
Los Angeles, CA (Sheraton Gateway Hotel at LAX)
CTAF will be examining various treatment options for migraine headaches. The topic is timely given the recent FDA approval of a new hand–held device producing transcranial magnetic stimulation (TMS) for treating migraines. CTAF's review will include evidence on major treatment options (i.e., this new device, various drug regimens, and alternative/ complementary therapies). CTAF’s public deliberation of the evidence will provide clarity and guidance to clinicians, insurers, and patients confronted with decisions on how best to treat migraines.